Takeda casts doubt on the remaining approach to amyloidosis
After last year’s flop of Prothena’s NEOD001, Takeda’s Ninlaro fails to treat the underlying cause of the non-genetic form of this disease.
Asco 2019 – tepotinib and capmatinib fight over a new lung cancer niche
cMet emerges as the latest genetic mutation that could soon see targeted treatments become available.
Upcoming events – key tests approach for Biogen and Kalvista
Biogen needs a win with its Tecfidera follow-on, while Kalvista hopes to make HAE where Biocryst failed.
Novartis sees hidden value in Xiidra
Novartis will need to boost Xiidra sales to justify the hefty price it has paid, but the Swiss company has form.
US big biotechs lag in the opening quarter of the year
A look at sector share prices in the opening three months of 2019 reveals a resurgent big pharma and a strong showing from the world’s other large drug makers, with US…
Upcoming events – Pfizer and Glycomimetics await sickle cell data and Biocryst tries again
Rivipansel needs to help sickle cell patients leave hospital sooner and BCX7353 faces established hereditary angioedema agents.
EASL 2019 preview – Viking and Spring Bank abstracts pique early interest
High-profile presentations from the likes of Intercept and Alnylam remain under wraps before Europe’s biggest liver disease conference next month, but the early abstract…
More Sanofi dengue setbacks could benefit Takeda
Sanofi might only get the US go-ahead for its dengue vaccine Dengvaxia in a narrow population, leaving the door open for its rival Takeda.
Off-the-shelf approaches keep cell therapy investors keen
Five months after Allogene’s flotation there are few signs of waning interest in new issues of cell therapy companies, and they all have one thing in common.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.